Sign In
Buy RYTM
$106.19
+4.80 (+4.73%)
At Close: Jun 23, 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
12:02pm, Wednesday, 17'th Jun 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
11:50am, Tuesday, 16'th Jun 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Why Is Rhythm Pharma Stock Jumping Today?
12:51pm, Monday, 15'th Jun 2026
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prade
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:28pm, Monday, 08'th Jun 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
02:58am, Wednesday, 03'rd Jun 2026
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE's recent FDA and EU a
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
08:00am, Friday, 29'th May 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
08:00am, Tuesday, 26'th May 2026
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
11:00pm, Wednesday, 13'th May 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
08:00am, Tuesday, 12'th May 2026
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
My Top 3 Stocks to Buy in May
04:44am, Thursday, 07'th May 2026
Forget "sell in May and go away." These stocks are good picks to buy and hold.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
02:04pm, Wednesday, 06'th May 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.
